Axonics® Announces Filing of Registration Statement for Proposed Initial Public Offering
Axonics Modulation Technologies, Inc. (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative implantable sacral neuromodulation (“SNM”) solutions for the treatment of overactive bladder (“OAB”), fecal incontinence (“FI”) and urinary retention (“UR”), announced today that it has filed an S-1 registration statement with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed public offering of its common stock.
Axonics has applied to list its common stock on the Nasdaq Global Market under the symbol “AXNX.” The number of shares to be offered and the price range for the proposed offering have not yet been determined. All shares of common stock to be sold in the offering will be offered by Axonics.
BofA Merrill Lynch and Morgan Stanley are acting as joint book-running managers for the proposed offering. Wells Fargo Securities is acting as lead manager and SunTrust Robinson Humphrey is acting as co-manager for the proposed offering.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to this offering, when available, may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at firstname.lastname@example.org; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, has developed an innovative rechargeable implantable SNM system (r-SNM™) for the treatment of patients with OAB, FI, and UR. The Company’s proprietary r-SNM system is designed to be 60% smaller than existing technology and to last approximately 15 years. Axonics currently has marketing approvals in Europe, Canada, and Australia for OAB, FI, and UR.
Axonics Modulation Technologies, Inc.
Dan Dearen, President & Chief Financial Officer
Investor & Media Contact
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Dataiku Raises $101 Million Series C to Transform and Democratize Enterprise AI Globally19.12.2018 18:00 | Tiedote
Dataiku Inc., one of the world’s leading enterprise data science and machine learning platforms, today announced a $101 million Series C funding round led by ICONIQ Capital and supported by Alven Capital, Battery Ventures, Dawn Capital, and FirstMark Capital. This announcement follows the company’s $28 million Series B in September 2017 and the release of Dataiku 5 in September 2018. Since its founding in 2013, Dataiku has focused on the vision of democratized data science as the key to uninhibited possibilities instead of restricted technologies reserved for the elite few. Today, Dataiku provides a platform that enables enterprises to fundamentally transform their business - global leaders use it to build AI that optimizes marketing budget, enables maintenance services, anticipate market trends or detects fraud, and more. “We’re very excited about what this latest funding round represents - it’s a confirmation of our vision to build and deliver the missing block for the modern enterpr
Universal Laser Systems Expands Its Materials Database with AOK Technologies, Solvay and 3M Materials19.12.2018 16:05 | Tiedote
Universal Laser Systems (ULS) announces the addition of AOK Technologies, Solvay and 3M™ materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The AOK Technologies, Solvay, and 3M materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: AOK Technologies TCK6 Thermally Conductive Insulator AOK Technologies TC1200 Thermally Conductive Insulator Solvay Udel® P-1700 Polysulfone (PSU) Solvay Ajedium™ Film Ultem® 1000-1000 Polyetherimide (PEI) 3M™ 1538L Rayon Acetate Woven Fabric Medical Tape Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advanta
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases19.12.2018 16:01 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005363/en/ Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be resp
Boeing-Leonardo Team Selects FLIR Systems EO/IR Surveillance Sensors for US Strategic Command UH-1N Replacement Contract19.12.2018 16:00 | Tiedote
FLIR Systems, Inc. (NASDAQ: FLIR) announced today it has been selected by Boeing to provide the FLIR Star SAFIRE 380-HDc EO/IR surveillance sensor for the United States Air Force (USAF) UH-1N replacement contract. The replacement program will replace the current fleet of USAF UH-1N helicopters, which support the service’s nuclear intercontinental ballistic missile bases in Wyoming, Montana and North Dakota. The aircraft will also be used for training, test and operational support airlift missions. The initial contract award to FLIR is for the first four helicopters, with the total contract up to 84 MH-139 helicopters and valued at more than $40 million to FLIR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005203/en/ FLIR will provide its Star SAFIRE 380-HDc airborne surveillance camera as part of the Boeing-Leonardo UH-1N replacement contract (Photo: Business Wire) Boeing was awarded a $375.5 million firm-fixed-price
BOC Group Listed as a Representative Vendor in the 2018 Gartner Market Guide for Enterprise Business Process Analysis19.12.2018 15:00 | Tiedote
The leading global provider of Enterprise Management Solutions, BOC Group, is pleased to share its recognition for its BPM suite ADONIS NP, in Gartner's latest Market Guide for Enterprise Business Process Analysis * . Thereby, BOC Group continues its recognition from the October 2018 Gartner Magic Quadrant and Critical Capabilities for Enterprise Architecture Tools reports for its EA suite ADOIT. Tobias Rausch, ADONIS product manager comments: “We are happy about getting recognized by Gartner, for the second time now, in their recently published Market Guide for Enterprise Business Process Analysis report. We see our placement in this year’s Market Guide as a testimony to our cutting-edge Business Process Analysis offering, and a validation that our strong focus on BPA is helping businesses in the digital transformation of their enterprise.” The Business Transformation Suite ADONIS NP is BOC Group's flagship product and Business Process Management and Analysis tool. This fully web-base
Slice Launch Studio Opens to Insurers and Tech Companies to Create Digital Insurance Products19.12.2018 15:00 | Tiedote
Slice Labs Inc., a leading on-demand insurance cloud platform provider, announced today the opening of the Slice Launch Studio in downtown Toronto, which is designed to be an innovation hub for Slice and its partners to ideate, experiment, test and deploy new on-demand insurance products on the Slice Insurance Cloud Services (ICS) platform. Insurers and technology companies from around the world can come to the Launch Studio to collaborate on Hackathons, a key step in Slice’s approach to getting product to market quickly. Slice will also host events year-round, bringing together thought leaders from across the globe to discuss and address emerging and increasing risks. Slice is currently working with insurers in the U.S., Canada, UK and SE Asia to launch new on-demand insurance products, using a minimum viable product methodology which allows for launch in under three months. The Co-operators Group is the pilot partner for the Launch Studio, who recently launched duuo, both its new dig
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme